Psychedelic Psychiatry's Brave New World.
David Nutt, David Erritzøe, Robin Carhart-Harris
Cell April 1, 2020 DOI: 10.1016/j.cell.2020.03.020 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Anxiety Depression Psychedelic-assisted therapy PTSD |
| Keywords | Psychedelics Therapeutic settings Guided sessions Psychedelic treatment Compounds Substances Mental health conditions Mental healthcare Psychological breakthroughs Transformative healing Clinical research Clinical investigations Studies Outcomes New paradigm |
| Citations | 330 |
| Key findings | Psilocybin and other 5-HT2A receptor agonists show promise for treating depression and addiction. |
Abstract
After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.